Lumos Pharma (NASDAQ:LUMO – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $28.00 price objective on the stock.
Several other research analysts have also commented on LUMO. EF Hutton Acquisition Co. I upgraded shares of Lumos Pharma to a “strong-buy” rating in a report on Tuesday. Oppenheimer reduced their target price on shares of Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd.
View Our Latest Research Report on Lumos Pharma
Lumos Pharma Trading Down 1.6 %
Lumos Pharma (NASDAQ:LUMO – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.33. The firm had revenue of $0.49 million during the quarter. Lumos Pharma had a negative return on equity of 157.99% and a negative net margin of 2,405.72%. During the same period last year, the firm posted ($1.09) EPS. As a group, equities analysts predict that Lumos Pharma will post -2.56 EPS for the current fiscal year.
Lumos Pharma Company Profile
Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.
See Also
- Five stocks we like better than Lumos Pharma
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Find and Profitably Trade Stocks at 52-Week Lows
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
- The Risks of Owning Bonds
- What Intuitive Machines’ Big NASA Contract Means for Investors
Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.